India, June 26 -- Replimmune Group Inc. (REPL), a clinical-stage biotechnology company, on Friday announced the FDA acceptance of the biological license application (BLA) for RP-1 in combination with nivolumab for the treatment of advanced melanoma.
Melanoma is the fifth most common cancer in the world, with over 112,000 new cases diagnosed this year in the U.S. alone. As one of the most fatal skin cancers, the disease causes about 8,500 deaths annually. Advanced melanoma is indicated by the spread of malignancy beyond the primary tumor, but treatment options remain limited for patients unresponsive to immune checkpoint blockade.
RP-1 (vusolimogene oderparepvec) is Replimmune's lead drug candidate and consists of an attenuated Herpes simp...